

**Table 6. Threshold analysis**

	<b>Trifluridine- tipiracil + bevacizumab</b>	<b>Regorafenib</b>	<b>Best supportive care</b>
	<b>Comparator 3<sup>rd</sup> line</b>	<b>Comparator 4<sup>th</sup> line</b>	<b>Comparator 5<sup>th</sup> line</b>
Net cost	¶¶	¶¶	¶¶
Threshold QALYs required (£20,000 per QALY)	¶¶	¶¶	¶¶
Threshold QALYs required (£30,000 per QALY)	¶¶	¶¶	¶¶
Overall survival difference (months)	1.87	5.76	8.67
Threshold quality of life given overall survival (£20,000 per QALY)	¶¶	¶¶	¶¶
Threshold quality of life given overall survival (£30,000 per QALY)	¶¶	¶¶	¶¶
QALY: quality adjusted life year ¶¶ commercial in confidence figure removed			